- Trial phase
- Approved
- Time to market
- Already on market since 1997; generic widely available since 2012.
- Why 3/10
- Plavix is an approved, marketed drug with no pending regulatory decision, no upcoming PDUFA date, no pivotal readout, and no new indication filing in the next ~12 months. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5. Plavix is also a very small part of Sanofi's diversified $50B+ revenue base, further limiting any single-drug impact.
There are no hard, dated binary catalysts for Plavix in the next 12 months. The Texas Attorney General lawsuit (filed November 2025) is the most significant active legal overhang, but as a state-level fraud case with no trial date set, it is not a scheduled binary event. Investors should monitor any settlement or court ruling in the Texas case, but Plavix is too small a revenue contributor at Sanofi to drive a material share-price move from legal outcomes alone.
Price Chart
Executive Summary
Plavix (clopidogrel) is a legacy antiplatelet drug that was first FDA-approved in 1997 and lost US patent exclusivity in 2012. It is now a mature, widely genericized product that generates modest revenue for Sanofi (roughly $1 billion annually versus the company's $50+ billion total). The drug has no pending regulatory catalysts, no upcoming pivotal readouts, and no new indication filings on the horizon. The main investor-relevant developments are ongoing litigation: Texas sued Sanofi and Bristol-Myers Squibb in November 2025 over alleged failure to disclose diminished efficacy in certain populations, while Hawaii settled similar claims for $700 million in May 2025. For a diversified giant like Sanofi, Plavix is a small, declining contributor with no binary catalysts ahead.
How It Works
Plavix is a blood thinner (antiplatelet) that prevents platelets in the blood from sticking together and forming clots. It works by blocking a specific receptor (P2Y12) on platelets, reducing the risk of heart attacks, strokes, and blood clots in patients with cardiovascular disease.
Trial Status
Plavix was FDA-approved on November 17, 1997. US composition-of-matter and market-exclusivity protections expired in 2012, and generic clopidogrel is widely available from multiple manufacturers. The drug remains marketed as a brand in certain international markets.
The Two-Sided Case
Upcoming Catalysts
- No scheduled FDA catalysts, PDUFA dates, or pivotal readouts for Plavix in the next 12 months.
- Texas Attorney General lawsuit (filed November 2025) is the most significant active legal overhang; any settlement or court ruling would be a watch item.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report